Evidence map›Paper›PMID 24637803›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014

Oxytocin-augmented social cognitive skills training in schizophrenia.

Michael C Davis, Michael F Green, Junghee Lee, William P Horan, Damla Senturk, Angelika D Clarke, Stephen R Marder

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 5 pooled it
22.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 5 syntheses or guidelines pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Review
  20. International perspective on social cognition in schizophrenia: current stage and the next steps.European psychiatry : the journal of the Association of European Psychiatrists · 2025
    Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Michael C Davis1] Department of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA [2] VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA.
Michael F Green1] Department of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA [2] VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA.
Junghee Lee1] Department of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA [2] VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA.
William P Horan1] Department of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA [2] VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA.
Damla SenturkDepartment of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
Angelika D Clarke1] Department of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA [2] VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA.
Stephen R Marder1] Department of Psychiatry and Biobehavioral Sciences, UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA [2] VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA.
Neurobehavioral Systems · USMental Illness Research, Education and Clinical Centers · USUCLA Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Impairments in social cognition are common in schizophrenia and predict poor functional outcome. The purpose of this proof-of-concept randomized, parallel group clinical trial was to assess whether intranasal oxytocin (OT), given before social cognitive training, enhances learning of social cognitive skills. Twenty seven male outpatients with schizophrenia participated in a 6-week (12 session) training on social cognitive skills. Training focused on three domains: facial affect recognition, social perception, and empathy. Subjects were randomly assigned (double blind) to receive either intranasal OTor placebo 30 min before each session. Participants did not receive OT between sessions or on the day of assessments. We evaluated scores on social-cognition measures, as well as clinical symptoms and neurocognition, at baseline, 1 week following the final training session, and 1 month later. Our prespecified primary outcome measure was a social-cognition composite score comprised of five individual measures. There were main effects of time (indicating improvement across the combined-treatment groups) on the social-cognition composite score at both 1 week and 1 month following completion of training. Subjects receiving OT demonstrated significantly greater improvements in empathic accuracy than those receiving placebo at both posttreatment and 1 month follow up. There were no OT-related effects for the other social cognitive tests, clinical symptoms, or neurocognition. This study provides initial support for the idea that OT enhances the effectiveness of training when administered shortly before social cognitive training sessions. The effects were most pronounced on empathic accuracy, a high-level social cognitive process that is not easily improved in current social cognitive remediation programs.

Indexed as

Social PerceptionAdministration, IntranasalAdultCentral Nervous System AgentsCognitionCognitive Behavioral TherapyCombined Modality TherapyDouble-Blind MethodEmpathyFacial ExpressionFollow-Up StudiesHumansMaleNeuropsychological TestsOutpatientsOxytocinCentral Nervous System AgentsOxytocin

Identifiers

PMID24637803
PMCPMC4104336
OpenAlexW2166079633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.